Recursion Pharmaceuticals, Inc. (RXRX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering.
Is Recursion Pharmaceuticals, Inc. stock overvalued or undervalued in 2026?
As of November 2, 2026, Recursion Pharmaceuticals, Inc. (RXRX) trades at $3.83 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Recursion Pharmaceuticals, Inc.
Market cap $2B · 52 weeks $2.84 – $5.44 (30 % below the high) · P/E no earnings · Dividend none · Next earnings March 3, 2027 · expected EPS -$0.22 · Closing price, Nov 2 · accounts published Nov 2.
- Valuation: P/Sales 23.4× (no earnings).
- Balance sheet: Distress zone (fragile).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 3 of 4 pass
- Cash Runway 24 months, borderline.
- Total Debt 0.1×, passes.
- R&D / Market cap 24.8 %, passes.
- Market cap / Cash 2.3×, passes.
- Annual cash burn $0.83, info.
Against its peers (reference peers) — Recursion Pharmaceuticals, Inc.: P/E —; EV/EBITDA —; ROIC -43.7 %; $2.3B. Harmony Biosciences Holdings, Inc. (P/E 12.3×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.2B), Aurinia Pharmaceuticals Inc. (P/E 7.0×; EV/EBITDA 11.4×; ROIC 20.9 %; $2.1B), ADMA Biologics, Inc. (P/E 15.8×; EV/EBITDA 10.9×; ROIC 27.6 %; $2.5B).
Profitability
| Return on Equity | -47.85% |
| Return on Invested Capital | -43.66% |
| Return on Assets | -38.93% |
| Gross Margin | 10.74% |
| Operating Margin | -725.44% |
| Net Margin | -697.13% |
Financial Health
| Debt / Equity | 0.08 |
| Current Ratio | 5.01 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 0.37 |
Price Performance
| 1 month | -7.04% |
| 3 months | +20.82% |
| Year-to-date | -6.36% |
| 1 year | -29.60% |
| 3 years | -35.19% |
| 5 years | -80.38% |
Related companies: DNLI · RLAY · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of RXRX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks